← Back to Clinical Trials
Recruiting NCT06258668

Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Moderate-to-severe Plaque Psoriasis
Sponsor Bristol-Myers Squibb
Study Type OBSERVATIONAL
Phase N/A
Enrollment 505
Sex ALL
Min Age 19 Years
Max Age N/A
Start Date 2024-08-21
Completion 2028-09-30
Interventions
Deucravacitinib

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.

Eligibility Criteria

Inclusion Criteria: * Adult participants ≥19 years of age * Diagnosis of moderate-to-severe plaque psoriasis * Candidate for phototherapy or systemic therapy * Will begin deucravacitinib according to approved product label Exclusion Criteria: * Participants prescribed deucravacitinib for therapeutic indications not approved in Korea * Participants for whom deucravacitinib is contraindicated as clarified in Korean prescribing information by ministry of food and drug safety (MFDS)

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE MODERATE-TO-SEVERE PLAQUE PSORIASIS TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}